Acute chest syndrome (ACS) usually presents in patients with sickle cell disease (SCD) as a rapidly occurring pulmonary disease recognized by lower respiratory tract symptoms, hypoxemia, and a new infiltrate shown on a chest radiograph. 1 ACS causes a high number of hospitalizations and deaths of children with SCD, and by some estimates, it accounts for as many as 25% of SCD-related deaths. [1] [2] [3] [4] Almost half of the patients diagnosed with ACS develop the respiratory complication during hospitalization for another diagnosis such as pain crisis. Factors such as young age, low baseline hemoglobin level, and low fetal hemoglobin level place patients at a higher risk of developing ACS. [3] [4] [5] [6] [7] Opioid analgesics, postoperative atelectasis, and asthma exacerbations or respiratory viral infections may promote the development of an ACS episode. [1] [2] [3] [4] [5] [6] [7] [8] [9] Although the etiology is undetermined in many cases, pulmonary infarction, fat embolism, and infection are now recognized as important causes of ACS. Chlamydia pneumoniae, Mycoplasma pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, and parvovirus are pathogens commonly isolated from patients with ACS. 2 Management of ACS is primarily supportive care and includes respiratory therapy (eg, incentive spirometry [IS] , positive expiratory pressure [PEP] , and bronchodilators), antibiotics, and red-cell transfusions (J. Myers, unpublished PowerPoint presentation, 2006, and refs [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] ). There have been few published studies proving the effectiveness of these measures in the management of ACS. In their study, Bellet et al 13 documented the efficacy of adequate analgesia in combination with IS in preventing ACS in patients admitted for vaso-occlusive crisis. Pain control prevented splinting and resulted in improved aeration and prevention of atelectasis. Other treatments either are empiric or their effectiveness has been inferred from studies that involved other complications of SCD (ie, transfusions and exchange transfusions after stroke). [1] [2] [3] [4] [5] [6] [7] At our own institution, we found that more than half of all children who received red-cell exchange transfusion for ACS did not show evidence of ACS at presentation, and the median time to exchange transfusion was 1 day. 23 In addition, we could detect no consistent criteria for performing an exchange transfusion.
In this article we discuss the development and, more importantly, the implementation of an evidence-based guideline for children and adolescents with SCD with ACS or at risk for ACS. The guideline was based on interventions to potentially decrease the development of ACS in those at risk, heightened vigilance for ACS detection, and aggressive treatment to prevent significant morbidity and mortality. We embarked on an implementation program, because data in the pilot study indicated that average length of stay had not been affected and pulmonary interventions and clinical respiratory score (CRS) assessments were not being administered according to the guideline. Outcome measures designed to evaluate success of the guideline included length of stay, number of exchange transfusions, average cost per SCD admission, and adherence to respiratory interventions. These outcomes indirectly measured morbidity and the efficiency of our practice. Implementation of this guideline demonstrated that even when evidence is limited, standardization of care can produce significant improvement in clinical outcomes.
METHODS

Guideline Development
Physicians from hematology, emergency medicine, critical care, and pulmonary medicine along with nursing and respiratory care served as content experts to establish the clinical practice guideline. Guideline development followed the standards established by the hospital's evidence-based outcomes center, which included review preparation, exploring existing internal and external guidelines, searching for relevant evidence from the past 15 years, critically analyzing research studies, and summarizing the evidence by preparing the guideline, order sets, and an interdisciplinary plan of care. Three systematic reviews from the Cochrane Database, 5 randomized clinical trials, 29 nonrandomized studies, and 16 review articles were used in the development of the guideline. Content experts met monthly over the course of 1 year to explore the evidence and establish critical components of the guideline.
Critical Components of the Guideline
Clinical history, physical examination, oxygen saturation level, and chest radiography were used to diagnose ACS. [1] [2] [3] [4] [5] [7] [8] [9] Here we used a broad clinical definition of ACS (ie, lower respiratory symptoms including hypoxemia or new lung infiltrate) rather than the narrower definition used for epidemiologic or clinical studies. Essential components of the history and examination are listed in Table 1 . To achieve standardization of respiratory assess- Table 2 ) ment, we integrated a CRS to measure the severity of respiratory distress. The CRS ranged from 0 to 12 and incorporated evaluation of the patient's respiratory rate, ausculation of the lung fields, use of accessory muscles, mental status, room-air oxygen saturation, and skin/mucosal color ( Table 2 ). Reliability of the CRS was first established with 314 children, aged 1 to 18 years, who presented to the emergency center with symptoms that suggested asthma. 24 Before implementing the new guideline, the CRS was examined in 73 children who presented to the emergency center with a diagnosis of SCD. The mean age of this group was 12 years. The Respiratory Distress Assessment Instrument (RDAI) was used to obtain a score of respiratory severity for comparison with the CRS each time it was assessed. The RDAI is a well-published scale that is similar in assessment categories to the CRS and measures adventitious lung sounds on expiration and inspiration and retractions observed in the supraclavicular, intercostal, and subcostal spaces. In the 73 children with SCD, there was a significant (P ϭ .004) association between the CRS and RDAI and the final disposition of the patients (being hospitalized or sent home). The receiver operating characteristic (ROC) curve was computed to evaluate accuracy of the CRS. The CRS at time of discharge from the emergency center was more sensitive in predicting discharge (ROC curve: 0.63) compared with the RDAI (ROC curve: 0.51). Test-retest reliability of the CRS instrument was determined by having a second health care provider rate a subset of patients with SCD independently within 15 minutes of each CRS measurement and then computing the correlation analysis. CRS correlations among 2 respiratory therapists who rated children at the time of emergency-center admission (P Ͻ .001), before treatment (P Ͻ .001), and after treatment (P Ͻ .001) were significant, which supports the scale as an effective clinical tool that can be used consistently by health care providers.
Respiratory therapists and physicians used the CRS to evaluate children with SCD who presented to the emergency center with respiratory illnesses and those at risk for developing ACS (fever, pain, vaso-occlusive disease). The CRS was used to guide treatment for all patients with SCD ( Table 2 ). All patients admitted on the ACS/SCD guideline received IS alternating with PEP (an airway-clearance device) therapy every 2 hours from 8 AM until 10 PM each day. Therapy continued beyond 10 PM if the patient was awake (Table 3) . Patients also received supplemental oxygen, if needed, to maintain oxygen saturations of Ն94% (Table 3 ). The IS and PEP were coordinated between nursing and respiratory care. Every 4 hours the patient was assessed by using the CRS, and the score was documented on the flow sheet (Table 3) . Respiratory interventions and the trigger for their implementation are outlined in the clinical algorithm (Fig 1) and are based on patient CRS.
In addition to CRS assessment and administration of respiratory interventions, the clinician's role included prompt interventions based on the clinical algorithm. Ensuring that pain was adequately managed, monitoring intake and output to prevent fluid overload, administering antibiotics as indicated, monitoring laboratory results, alerting the physician team if the hemoglobin transfusion threshold had been reached, and ambulating patients at least twice daily were important care strategies (Table 3) . Nurses and respiratory therapists were responsible for communicating with the medical team when CRSs escalated and assisting with patient transfers to a higher level of care as needed. Children with wheezing or rales/crackles present received specific attention, including steroid administration (Fig 1) . Discharge criteria also were established to avoid unnecessary variations in length of stay (Table 4 ). All patients with recurrent or severe ACS were referred to a SCD pulmonary clinic.
In addition to the guideline, physician order sets were developed for use in the emergency center and outpatient hematology clinic and on the acute care floors. The essential components of the diagnoses and management of children at risk for ACS and those with ACS are outlined in Table 3 . Note that those children at risk for ACS were monitored for development of ACS and received interventions to potentially decrease its development.
Guideline Implementation
The specific aim of implementation was to improve utilization and compli- for Healthcare Improvement's plando-study-act (PDSA) model to document a test of change with the ACS/ SCD guideline. 25, 26 PDSA is a systematic approach to problem-solving and a 4-step process for continuous quality improvement. Interventions and data from 2 PDSA cycles (phases 1 and 2) are summarized below. Pilot data were collected before the onset of the first PDSA cycle. Pilot data provided the implementation team with baseline measures to compare with future assessments after the guideline was implemented. As a result of the pilot data, specific barriers to implementation were identified, and an education initiative was launched to address these issues.
Education
Phase 1/PDSA 1
The ACS/SCD guideline was designed for use by multiple specialties throughout the hospital. All specialties routinely caring for patients with SCD were identified from the pilot data, and education sessions were developed for each specialty. Individualized in-services were held for staff from the emergency center, inpatient hematology-oncology unit, general medicine, float pool staff, progressive care unit, outpatient hematology clinic, and respiratory care. Physicians, fellows, and residents who work in these specialty areas were educated on the ACS/SCD guideline through noon conferences, education modules, lectures, educational lunches, and grand rounds. Presentations provided a brief description of ACS and its complications, reasons for implementing the guideline, and bullet points with information pertinent to the physician, nurse, and respiratory therapist roles in caring for patients with SCD. Case scenarios were presented to allow staff to apply the guideline to real-life situations. A frequentlyasked-questions hand-out was given to use as a quick reference guide (Fig  2) . In addition, a video describing pulmonary pathophysiology, and the rationale for the guideline's pulmonary interventions, was developed and placed on the hospital's intranet site to augment live in-services.
FIGURE 1
Clinical algorithm for ACS respiratory support management. PO indicates by mouth; IV, intravenous; SPO 2 , oxygen saturation; IPV, intrapulmonary percussive ventilation; BID, twice daily; TID, three times daily; GI, gastrointestinal; Hb, hemoglobin; BiPAP, bilevel positive airway pressure. 
Phase 2/ PDSA 2
Initial evaluation of guideline usage after implementation of the education initiative revealed a deficit in documentation of both the CRS and pulmonary interventions. The second PDSA cycle focused on improving documentation of these 2 components. Small group meetings with nursing and respiratory care representatives from the implementation team were held. Data from the first PDSA cycle were shared with nursing and respiratory care educators and managers, who then disseminated the data to their colleagues, highlighting opportunities for quality improvement. The guidelineimplementation coordinator also presented the data and solicited feedback from nurses at shift report on all inpatient units. In addition, CRS badge cards with the CRS scale and bulleted points essential to the ACS/SCD guideline were given to nurses on the 3 units that received the highest volume of children admitted with SCD.
Methods of Evaluation
Pilot Study
A retrospective chart review was performed for all guideline-eligible patients (all patients from 1 to 21 years of age admitted with SCD) from February through March of 2009. Data on length of stay, number of exchange transfusions, and documentation of pulmonary interventions and CRS assessments for the first 3 days of admission were collected for each SCD admission.
Phase 1/PDSA 1
A data-collection form was developed to capture outcome measures established by the implementation team for the 2 subsequent PDSA cycles. A retrospective chart review was performed for all guideline-eligible patients from October through November of 2009. Data on length of stay and number of exchange transfusions over the entire inpatient stay for each patient with SCD were also collected. Data on the average cost per patient admission for SCD were obtained from a financial analyst who searched a database by using All-Patient Refined DiagnosisRelated Groups codes.
Data on documentation of CRS and pulmonary interventions for the first 3 inpatient days for every patient with SCD were collected. As indicated in the guideline, the CRS was to be assessed every 4 hours and supervised IS/PEP therapy administered every 2 hours between the hours of 8 AM and 10 PM. These responsibilities were shared between nursing and respiratory care. The number of opportunities for nurses/respiratory therapists to document the CRS and pulmonary interventions administered was compared with the number of times there was actual documentation of the CRS and pulmonary interventions performed.
Phase 2/PDSA 2
Identical methods of evaluation were used for the second PDSA cycle, because the same outcome measures were monitored. Data on patient admissions for SCD from June through August of 2010 were collected for the second PDSA cycle.
In addition to the data collected in the 2 PDSA cycles, data on average length of stay for patients with SCD were evaluated in fiscal years 2007, 2008 , and 2009 and the first 6 months of fiscal year 2010. These data were obtained from a financial analyst who searched a database by using All-Patient Refined Diagnosis-Related Groups codes.
We did not obtain institutional review board approval for this retrospective analysis, because it was a qualityimprovement exercise, not a research study.
FIGURE 2
Frequently-asked-questions (FAQ) hand-out provided to inpatient nurses caring for patients with SCD with ACS or at risk for ACS.
Analysis
Minitab statistical software (Minitab Inc, State College, PA) was used to analyze the data. A 2-sample t test was run to evaluate the difference in length of stay between the pilot data and each of the 2 PDSA cycles. A 2-proportions test was run to assess if there was a difference in documentation of the CRS and pulmonary interventions between the initial pilot data and the data collected after the interventions in each of the 2 PDSA cycles.
RESULTS
The guideline was developed and instituted in February 2008 after informal education interventions with nursing, respiratory care, and physician groups. The average length of stay did not appreciably change from preguideline development in 2007 to up to 22 months after institution of the guideline. The formal implementation team was initiated in the summer of 2009.
Three measurement periods were used to evaluate the formal implementation of the ACS/SCD guideline. In the pilot study conducted from January to February of 2009, 1 year after the guideline was completed and instituted, 59 patients older than 1 year with SCD and at risk for ACS or with ACS were admitted. Fifty-five charts were available for review; 1 patient with a prolonged length of stay of 38 days was removed from analysis, because the extended hospitalization was unrelated to ACS. Sixty-two patients older than 1 year were admitted from October to November of 2009; 61 charts were available for review for the first PDSA cycle evaluation, because 1 patient had a prolonged length of stay of 25 days and was not included because the extended hospitalization was unrelated to ACS. Twenty-four patients older than 1 year were admitted from June through August of 2010, and all were reviewed and included in the analysis of the second PDSA cycle.
The discharge criteria facilitated decision-making at the time of discharge and decreased length of stay by standardizing the approach to discharge. Average length of stay was reduced from 5.8 days during the pilot study before implementation to 4.1 days after the second PDSA cycle, which is a reduction of 1.7 days (29%) (95% confidence interval for difference: 0.1-3.2) ( Table 5 ). No patients in the pilot study or the 2 PDSA-cycle evaluations received an exchange transfusion. Average cost per SCD admission decreased from $30 359 in fiscal year 2008 before implementation of the guideline to $22 368 in the first 6 months of 2010, which is a reduction of $7991 (26.3%). On average, this hospital admits 357 patients per year for SCD. The reduced average cost per admission would result in an annual savings of more than $2 850 000. Documentation of the CRS increased from 31% before implementation of the guideline to 75.5% after the second PDSA cycle, which is an improvement of 44.5% (95% confidence interval for difference: 38.7%-50.2%). Documentation of IS/PEP increased from 23% before implementation of the guideline to Ͼ50% after the second PDSA cycle, which is an improvement of 27% (95% confidence interval for difference: 21.3%-33.0%) ( Table 5 ). Patients with a higher CRS in the emergency center were more likely to receive a simple blood transfusion while hospitalized (P Ͻ .001). CRS in the emergency center was not related to the patient's length of stay or transfer to the critical care unit. 
DISCUSSION
The mainstay of successful treatment for children with SCD with ACS or at risk for ACS is high-quality supportive care. Implementation of a standardized approach to care for children at risk for ACS and those with ACS revealed significant changes in clinical outcomes. Standardizing fluid management, maintaining oxygenation, administering respiratory interventions, and ensuring pain control were essential elements of quality care for these patients. We also instituted an aggressive respiratory monitoring and therapy program. In addition, using the CRS afforded us a common language for describing the condition of these children to each other and driving treatment and triage. The use of the CRS as a standardized method for evaluating clinical respiratory status played an important role in minimizing variation in assessment as well as management for these children.
The decision whether to institute an exchange transfusion, and determinants of the need for acute respiratory moni- toring, were inconsistent and undefined before the guideline's development. On the basis of results from our earlier study, 23 it is remarkable that no exchange transfusions were needed for children with ACS during the 3 monitoring periods. Thus, we believe a standardized approach to exchange transfusion resulted in decreased use of this therapy during the initial roll-out of the protocol even before the guideline was formally implemented. One explanation is the fairly rapid adoption of the guideline by our critical care service.
It is important to recognize the critical role of implementation in improving patient outcomes. The guideline was formally implemented in the summer of 2009, more than 1 year after the guideline's development and dissemination. It was only after implementation that patient outcomes improved. Data showed the step-wise improvement in outcomes from the pilot data collected before implementation through each of the 2 implementation phases (Table 5 ).
The change in average cost per SCD admission is impressive. This decrease is most likely attributable to the decrease in average length of stay and room charges for SCD admissions after implementation of the guideline.
One of the resources required for implementation included a master's level trained implementation coordinator. This person coordinated implementation programs for several evidencebased guidelines and devoted approximately one-third of her time to this project. In addition, the implementation team was vital to the project's success. Although we saw improvements in outcomes for patients with SCD, we identified a number of barriers to and opportunities for quality improvement after the second and final PDSA cycle. Documentation of the CRS and IS was poorer on those units that received a lower volume of admissions for SCD. In addition, nurses documented less than respiratory care providers on all units, which may have been, in part, because of the chart design. Nurses now are required to document in 2 different places. As our institution goes live with computerized physician order entry and electronic chart documentation this year, one of our next PDSA cycles may include examining ways to improve documentation by modifying the nursing flow chart in our institution's electronic medical record. These issues highlight the fact that quality improvement is an ongoing process.
There are limitations to this qualityimprovement project. The number of charts reviewed in the second phase of implementation was significantly less than the number reviewed in the pilot study and the first phase of implementation. There were fewer SCD admissions during this period. We could not detect the specific mechanisms by which implementation improved outcomes; thus, we do not know which portions of the guideline may be critical to its success.
It is unlikely that the outcomes of this quality-improvement project were influenced by other systematic changes during the implementation period. The institution's practices concerning discharge did not change after the guideline was developed. In addition, there was no difference in severity of ACS presentations over the course of the guideline's development and implementation. We do not have data on the use of hydroxyurea during this period. It is possible that an increase in the use of this drug in the population of patients with SCD had an impact on clinical outcomes, but we feel that the reduction in average length of stay can be attributed to both improvements made in the administration and documentation of the CRS and pulmonary interventions and the avoidance of exchange transfusions.
CONCLUSIONS
Standardization of care improves clinical outcomes for patients with SCD who are at risk for ACS or have ACS. It is even more important to note that standardization of care did not result from guideline development alone but also from implementation efforts. We advocate for, and encourage other providers of patients with SCD to adopt, an evidence-based model of care and to devote the resources necessary for implementation. The results of this project indicate that both components are vital for improving the clinical outcomes of patients with SCD.
